Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Janux Therapeutics, Inc.NASDAQ: JANX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 62.67M shares rose 1.4% year over year, behind the +9.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.4% toward the trailing-twelve-month pace of +9.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
62.67M+1.1% QoQ
Last fiscal yearDec 2025
61.97M+15.3% YoY
LTMMar 2026
62.14M+9.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.4%——
1 year+15.3%——
3-year CAGR+14.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
61.97M USD
Year-over-year change
+15.3%
4-year CAGR
+10.7%

Weighted Avg Shares (Diluted) vs competitors

How JANX compares with its peers on the latest reported figures

  • JANX's LTM Mar 2026 weighted avg shares (diluted) of 62.14M shares is the 8th highest of the 10 companies compared; the peer median is 106.83M shares.
  • Its year-over-year change of +9.2% is the 5th highest of 10, against a peer median of +9.0%.
  • Over three fiscal years its annual growth of +14.3% compares with a peer median of +14.5%.
JANX Competitors Peer median
Weighted Avg Shares (Diluted) for JANX and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026189.27M +2.9%+5.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.2%+28.0%
IMTXImmatics N.V.LTM Mar 2026125.95M +13.3%+21.1%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
JANXJanux Therapeutics, Inc.LTM Mar 202662.14M +9.2%+14.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+8.2%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding JANX) 106.83M+9.0%+14.5%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.